# Efficacy of Atenativ in Patients With Congenital Antithrombin Deficiency Undergoing Surgery or Delivery

> **NCT04918173** · PHASE3 · RECRUITING · sponsor: **Octapharma** · enrollment: 38 (estimated)

## Conditions studied

- Congenital Antithrombin Deficiency

## Interventions

- **DRUG:** Atenativ

## Key facts

- **NCT ID:** NCT04918173
- **Lead sponsor:** Octapharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-07-01
- **Primary completion:** 2026-06-01
- **Final completion:** 2026-06-01
- **Target enrollment:** 38 (ESTIMATED)
- **Last updated:** 2025-11-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04918173

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04918173, "Efficacy of Atenativ in Patients With Congenital Antithrombin Deficiency Undergoing Surgery or Delivery". Retrieved via AI Analytics 2026-07-08 from https://api.ai-analytics.org/clinical/NCT04918173. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*